Cantor Fitzgerald Reiterates Overweight on X4 Pharmaceuticals, Maintains $3 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
Cantor Fitzgerald analyst Kristen Kluska reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Overweight and maintains $3 price target.
Cantor Fitzgerald analyst Kristen Kluska reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Overweight and maintains $3 price target.